Sustained and targeted delivery of siRNA/DP7‐C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy

• DOI: 10.1111/cas.14903
• Publication Date: 2021-04-01T03:04:56Z
• Authors: Binyan Zhao; Bailing Zhou; Kun Shi; Rui Zhang; Chunyan Dong; Daoyuan Xie; Lin Tang; Yaomei Tian; Zhiyong Qian; Li Yang
• Keywords: Liver Cancer

Abstract Hepatocellular carcinoma (HCC) is one of the most lethal cancers in humans. The inhibition peptidyl‐prolyl cis / trans isomerase (Pin1) gene expression may have great potential treatment HCC. N ‐Acetylgalactosamine (GalNAc) was used to target liver. Cholesterol‐modified antimicrobial peptide DP7 (DP7‐C) acts as a carrier, GalNAc‐siRNA/DP7‐C complex increases uptake GalNAc‐siRNA and escape endosomes hepatocytes. In addition, DP7‐C nanoparticles hydrogel‐assisted GalNAc‐Pin1 siRNA delivery can effectively enhance stability prolong silencing effects Pin1 siRNA. an orthotopic liver cancer model, siRNA/DP7‐C/hydrogel potentially regulate hepatocellular cells inhibit tumor progression. Our study proves that efficient method for HCC provides sustainable effective drug system suppression cancer.